Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in a Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn’s disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR300, a G-protein-coupled receptor modulator for IBD and potentially other immune-mediated diseases; PRA052, an anti-CD30L mAb for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; and PR2100, an anti-inflammatory cytokine mAb for IBD and inflammatory and fibrotic diseases. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 1995 and is based in San Diego, California. As of June 16, 2023, Prometheus Biosciences, Inc. operates as a subsidiary of Merck & Co., Inc.